Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABDX.L
HOLDAbingdon Health Plc · Healthcare · United Kingdom · $34M · Avg Vol: $14K/d
COMPANY DESCRIPTION
Abingdon Health Plc is a leading lateral flow contract development and manufacturing organization (CDMO), providing end-to-end services for rapid diagnostic tests. The company serves global clients across clinical, animal health, plant health, and environmental sectors, leveraging its state-of-the-art UK manufacturing facilities. Its competitive moat is built on specialized technical expertise in lateral flow assay development, regulatory navigation, and highly scalable automated production lines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7M | 5.3M | 8.1M | 11.1M | 43.8% | 12.6M | 16.1M | 20.0M | 34.1% |
| EPS | -0.05 | -0.01 | -0.01 | -0.01 | — | -0.01 | — | — | — |
| Shares | 251.1M | 251.1M | 126.7M | 193.6M | -22.9% | 251.1M | — | — | — |
| Debt | 1.7M | 1.3M | 1.4M | 1.4M | -7.0% | 1.3M | — | — | — |
| Equity | 8.5M | 3.9M | 3.0M | 7.0M | -6.2% | — | — | — | — |
| Op CF | -10.2M | 1.2M | -2.2M | -4.2M | — | -3.0M | — | — | — |
| Inv CF | -1.0M | -88.4K | -30.4K | -1.9M | — | — | — | — | — |
| Fin CF | 7.8M | -9.2K | -0.2M | 6.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABDX.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABDX.L | Abingdon Health Plc(you) | $34M | 41 | HOLD |
| HVO.L | hVIVO plc | $63M | 36 | HOLD |
| CLBX.L | CelLBxHealth plc | $39M | 16 | STRONG SELL |
| GDR.L | genedrive plc | $28M | 16 | STRONG SELL |
| EDX.L | EDX Medical Group Plc | $65M | 6 | STRONG SELL |
| PXS.L | Provexis plc | $39M | 44 | HOLD |
| AREC.L | Arecor Therapeutics plc | $34M | 58 | HOLD |
| IXI.L | IXICO plc | $25M | 24 | SELL |
| SAR.L | Sareum Holdings plc | $38M | 19 | STRONG SELL |
| SBTX.L | SkinBioTherapeutics plc | $42M | 19 | STRONG SELL |
Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 56.9%